SAMHSA Urges States to Prepare for FDA-Approved Psychedelic Therapies

The U.S. federal agency SAMHSA is recommending that states begin strategic planning now for the potential FDA approval and implementation of psychedelic-assisted therapies. This proactive guidance reflects emerging clinical evidence supporting psilocybin and MDMA-assisted treatments for treatment-resistant conditions. States should develop regulatory frameworks, training programs, and healthcare infrastructure to integrate these novel therapies once federally approved. This preparation is critical for ensuring equitable access and proper clinical oversight when these therapies become available to patients.